Quick Links
University of California,
San Diego (UCSD)
Rebecca and John Moores UCSD
Cancer Center
La Jolla, CA
The Burnham Institute
La Jolla, CA
Dana Farber Cancer Institute
Harvard Medical School
Boston, MA
Johns Hopkins University
Oncology Center
Baltimore, MD
Long Island Jewish Medical
Center
Division of Hematology/Oncology
New Hyde Park, NY
M.D. Anderson Cancer Center
Houston, TX
Ohio State University
Cancer Center
Columbus, Ohio
Barts Cancer Centre of
Excellence
Barts Hospital
West Smithfield, London
Mayo Clinic
Rochester, MN
OFAR
Protocol
Participating Sites
M.D. Anderson Cancer Center
Houston, TX
Pending at:
University of California,
San Diego (UCSD)
Rebecca and John Moores
UCSD Cancer Center
La Jolla, CA
Please contact the participating site to setup an appointment or to get more informaiton.
CRC 009: A Phase I-II Study of Rituximab, Oxaliplatin, Fludarabine
and Cytarabine in Patients with Richter's Transformation, Prolymphocytic
Leukemia or Refractory/Relapsed B-Cell Chronic Lymphocytic Leukemia
Determine the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of oxaliplatin in combination with fludarabine, cytarabine and rituximab in patients with Richter’s transformation, prolymphocytic leukemia (PLL), or refractory/relapsed B-cell chronic lymphocytic leukemia (CLL). Assess the complete response (CR) and partial response (PR) rate to combination therapy of oxaliplatin, fludarabine, cytarabine and rituximab in patients with Richter’s transformation, PLL or refractory/relapsed B-cell CLL. Determine the safety and toxicity profile of combination therapy of oxaliplatin, fludarabine, cytarabine and rituximab in patients with Richter’s transformation, PLL or refractory/relapsed B-cell CLL.